The relationship between cyclooxygenase-2 expression and characteristic of malignant transformation in human colorectal adenomas

European Journal of Gastroenterology and Hepatology

Volumn 16, Issue 6, 2004, Pages 619-625

  Sheehan, Katherine M ^a,b   O'Connell, Fionnuala ^a,b   O'Grady, Anthony ^a,b   Conroy, Ronan M ^a   Leader, Mary B ^a,b   Byrne, Michael F ^a   Murray, Frank E ^a,b   Kay, Elaine W ^a,b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

Author keywords

Colon carcinogenesis; Colorectal adenoma; Colorectal cancer; Cyclooxygenase 2

Indexed keywords

CYCLOOXYGENASE 2;

ADENOMATOUS POLYP; ARTICLE; CANCER GRADING; CANCER INVASION; CELL HYPERPLASIA; COLORECTAL TUMOR; CONTROLLED STUDY; DISEASE SEVERITY; ENDOSCOPIC BIOPSY; EPITHELIUM DYSPLASIA; EVALUATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MEDICAL ASSESSMENT; POLYPECTOMY; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE FIXATION; TISSUE SECTION; TUMOR VOLUME; VILLOUS ADENOMA;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; CELL TRANSFORMATION, NEOPLASTIC; COLON; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERPLASIA; IMMUNOENZYME TECHNIQUES; ISOENZYMES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PRECANCEROUS CONDITIONS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 2542580817     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200406000-00017     Document Type: Article

References (55)

1. Globocan 2000. Cancer Incidence, Mortality and Prevalence: Worldwide Estimates, 2000. Lyon: IARCPress; 2001.
2. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1997; 87:159-170.
3. O'Brien MJ, Winawer SJ, Zauber AG, Gottlieb LS, Sternberg SS, Diaz B, et al. The National Polyps Study: patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology 1990; 98:371-379.
4. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular and molecular biology. Annu Rev Biochem 2000; 69:145-182.
5. Shift SJ, Rigas B. NSAIDs and colorectal cancer: evolving concepts of their chemopreventative actions. Gastroenterology 1997; 113:1992-1998.
6. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and carcinomas. Gastroenterology 1994; 107:1183-1188.
7. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, et al. Expression of cyclooxygenase-1 and -2 in human colon cancer. Cancer Res 1995; 55:3785-3789.
8. DuBois RN, Giardello FM, Smalley WE. Nonsteroidal anti inflammatory drugs, eicosanoids and colorectal cancer prevention. Gastroenterol Clin North Am 1996; 25:773-791.
9. Williams CS, Luongo C, Radhika A, Zhang T, Lamps LW, Nanney LB, et al. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 1996; 111:1134-1140.
10. Δ716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell 1996; 87:803-809.
11. Moorghen M, Ince P, Finney KJ, Sunter JP, Appleton DR, Watson AJ. A protective effect of sulindac against chemically induced primary colonic tumors in mice. J Pathol 1988; 156:341-347.
12. Shiff SJ, Qiao L, Tsai L, Rigas B. Sulindac sulfide, an aspirin like compound, inhibits proliferation, causes cell cycle quiescence and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 1995; 96:491-503.
13. Sandler RS, Galanko JC, Murray SC, Helm JF, Woosley JT. Aspirin and NSAID agents and risk for colorectal adenomas. Gastroenterology 1998; 114:441-447.
14. Logan RF, Little J, Hawtin PG, Hardcastle JD. Effect of aspirin and NSAIDs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. Br Med J 1993; 307:285-289.
15. Thun MJ, Namboodiri MM, Health CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325:1593-1596.
16. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, et al. Treatment of colonic and rectal adenoma with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328:1313-1316.
17. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342:1946-1952.
18. Hasegawa K, Ichikawa W, Fujita T, Ohno R, Okusa T, Yoshinaga K, Sugihara K. Expression of cyclooxygenase-2 mRNA in human colorectal adenomas. Eur J Cancer 2001; 37:1469-1474.
19. Sheehan KM, Sheahan K, O'Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ, Murray FE. The relationship between cyclooxygenase-2 expression and colorectal cancer. J Am Med Assoc 1999; 282: 1254-1257.
20. Fujita T, Matsui M, Takaku K, Uetake H, Ichikawa W, Taketo MM, Sugihara K. Size and invasion dependent increase in cyclooxygenase-2 levels in human colorectal carcinomas. Cancer Res 1998; 58:4823-4826.
21. Yang VW, Shields JM, Hamilton SR, Spannhake EW, Hubbard WC, Hylind LM, et al. Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res 1998; 58:1750-1753.
22. Narisawa T, Kusaka H, Yamazaki Y, Takahashi M, Koyama H, Koyama K, et al. Relationship between blood plasma prostaglandin E2 and liver and lung metastases in colorectal cancer. Dis Colon Rectum 1990; 33: 840-845.
23. Chapple KS, Cartwright EJ, Hawcroft G, Tisbury A, Bonifer C, Scott N, et al. Localisation of cyclooxygenase-2 in human sporadic colorectal adenomas. Am J Pathol 2000; 156:545-553.
24. Arao J, Sano Y, Fujii T, Kato S, Fu KI, Yoshino T, et al. Cyclooxygenase-2 is over expressed in serrated adenoma of the colorectum. Dis Colon Rectum 2001; 44:1319-1323.
25. Shamma A, Yamamoto H, Doki Y, Okami J, Kondo M, Fujiwara Y, et al. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin Cancer Res 2000; 6:1229-1238.
26. Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE. Cyclooxygenase-2 expression in the Barrett's metaplasia dysplasia adenocarcinoma sequence. Am J Gastroenterol 2001; 96:990-996.
27. Nathan CA, Leskov IL, Lin M, Abreo FW, Shi R, Hartman GH, Glass J. COX-2 expression in dysplasia of the head and neck: correlation with elF4E. Cancer 2001; 92:1888-1895.
28. Sheng GG, Shao J, Sheng H, Hooton EB, Isakson PC, Morrow JD, et al. A selective cyclooxygenase-2 inhibitor suppresses the growth of H-ras transformed rat intestinal epithelial cells. Gastroenterotogy 1997; 113:1883-1891.
29. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83:493-501.
30. Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A, Dannenberg AJ. Inhibition of COX-2 gene expression by p53. J Biol Chem 1999; 274:10911-10915.
31. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal tumor development. N Engl J Med 1988; 319:525-532.
32. Fujita M, Fukui H, Kusaka T, Morita K, Fujii S, Ueda Y, et al. Relationship between cyclooxygenase-2 expression and K-ras gene mutation in colorectal adenomas. J Gastroenterol Hepatol 2000; 15:1277-1281.
33. Jacoby RF, Marshall DJ, Newton MA, Novakovic K, Tutsch K, Cole CE, et al. Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the non-steroidal anti inflammatory drug piroxicam. Cancer Res 1996; 56:710-714.
34. Barnes CJ, Lee M. Chemoprevention of spontaneous intestinal adenomas in the Apc min mouse model with aspirin. Gastroenterology 1998; 114:873-877.
35. Hull MA, Booth JK, Tisbury A, Scott N, Bonifer C, Markham AF, Coletta PL, et al. Cyclooxygenase-2 is up regulated and localised to macrophages in the intestine of Min mice. Br J Cancer 1999; 79:1399-1405.
36. Shattuck-Brandt RL, Varilek GW, Radhika A, Yang F, Washington MK, DuBois RN. Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL10 (-/-) mice. Gastroenterology 2000; 118:337-345.
37. Muller-Decker K, Albert C, Lukanov T, Winde G, Marks F, Furstenberger G. Cellular localization of cyclooxygenase isozymes in Crohn's disease and colorectal cancer. Int J Colorectal Dis 1999; 14:212-218.
38. Khan KN, Masferrer JL, Woerner BM, Soslow R, Koki AT. Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon. Scand J Gastroenterol 2001; 36:865-869.
39. Bamba H, Ota S, Kato A, Adachi A, Itoyama S, Matsuzaki F. High expression of COX-2 in macrophages of human colonic adenoma. Int J Cancer 1999; 83:470-475.
40. Kutchera W, Jones DA, Matsunami N, Groden J, McIntyre TM, Zimmerman GA, et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci 1996; 93:4816-4820.
41. Nolan RD, Danilowicz RM, Eling TE. Role of arachidonic acid metabolism in mitogenic response of BALB/c 3T3 fibroblasts to epidermal growth factor. Mol Pharmacol 1988; 33:650-656.
42. Lewis JS, Landers RJ, Underwood JC, Harris AL, Lewis CE. Expression of vascular endothelial growth factor by macrophages is regulated in poorly vascularised areas of breast carcinomas. J Pathol 2000; 192:150-158.
43. Huang ZF, Massey JB, Via DP. Differential regulation of cyclooxygenase-2 (COX-2) mRNA by interleukin-1 beta and tumor necrosis factor alpha in human in vitro differentiated macrophages. Biochem Pharmacol 2000; 59:187-194.
44. Nakajima T, Hamanaka K, Fukuda T, Oyama T, Kashiwabara K, Sano T. Why is cyclooxygenase-2 expressed in the neuroendocrine cells of the human alimentary tract? Pathol Int 1997; 47:889-891.
45. Uefuji K, Ichikura T, Mochizauki H. Expression of COX-2 in human gastric adenomas and adenocarcinomas. J Surg Oncol 2001; 76:26-30.
46. Maekawa M, Sugano K, Sano H, Miyazaki S, Ushiama M, Fujita S, et al. Increased expression of cyclooxygenase-2 to -1 in human colorectal cancers and adenomas, but not in hyperplastic polyps. Jpn J Clin Oncol 1998; 28:421-426.
47. Iino H, Jass JR, Simms LA, Young J, Leggett B, Ajioka Y, Watanabe H. DNA microsatellite instability in hyperplastic polyps, serrated adenomas, and mixed polyps: a mild mutator pathway for colorectal cancer? J Clin Pathol 1999; 52:5-9.
48. Jass JR, Whitehall VL, Young J, Leggett BA. Emerging concepts in colorectal neoplasia. Gastroenterology 2002; 123:862-876.
49. Karnes WE Jr, Shattuck-Brandt R, Burgart LJ, DuBois RN, Tester DJ, Cunningham JM, et al. Reduced COX-2 protein in colorectal cancer with defective mismatch repair. Cancer Res 1998; 58:5473-5477.
50. Sinicrope FA, Lemoine M, Xi L, Lynch PM, Cleary KR, Shen Y, Frazier ML. Reduced expression of cyclooxygenase-2 proteins in hereditary non polyposis colorectal cancers relative to sporadic cancers. Gastroenterology 1999; 117:350-358.
51. Hao X, Bishop AE, Wallace M, Wang H, Willcocks TC, et al. Early expression of cyclooxygenase-2 during sporadic colorectal carcinogenesis. J Pathol 1999; 187:295-301.
52. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93:705-716.
53. Marnett LJ. Aspirin and the potential role of prostaglandins in colorectal cancer. Cancer Res 1992; 52:5575-5589.
54. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci 1997; 94:3336-3340.
55. Levy GN. Prostaglandin H synthases, non steroidal anti-inflammatory drugs and colon cancer. FASEB J 1997; 11:234-247.